Gossamer Bio, Inc. (GOSS)

Several events have impacted Gossamer Bio's stock price over the past six months. The company reported a net loss in Q2 2025, but the stock surged due to investor interest in its clinical programs. Enrollment was completed in the Phase 3 PROSERA study for PAH, with topline results expected in February 2026. A net loss was reported for Q3 2025, though revenue from collaborations increased. Barclays initiated coverage with an "Overweight" rating, and the company holds a consensus "Moderate Buy" rating. Gossamer Bio was added to the S&P Biotechnology Select Industry Index. The stock has decreased in the past month but increased over the last 12 months.

As a clinical-stage biopharmaceutical company, Gossamer Bio, Inc. does not have traditional demand seasonality for commercialized products or services. Its activities revolve around research, development, and clinical trials, with financial performance driven by clinical trial milestones, regulatory approvals, and funding.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in immunology, inflammation, and oncology. Their lead product candidate is seralutinib (GB002), an inhaled small molecule inhibitor in Phase 3 clinical trials for pulmonary arterial hypertension (PAH) and being developed for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's strategy has narrowed to focus on seralutinib after discontinuing development on other candidates.

Gossamer Bio, Inc. is headquartered in San Diego, California, and has a European office in Dublin, Ireland. The company operates worldwide in its efforts to discover, acquire, develop, and commercialize therapeutics.

Gossamer Bio's brand reputation has been shaped by its focus on seralutinib and the progress of its clinical trials. The decision to lay off staff and halt development on other drug candidates to concentrate on seralutinib likely had a negative impact. Positive developments such as FDA designations and clinical advancements, along with continued research in lung-related conditions, could positively influence its reputation. The ongoing Phase 3 PROSERA study for PAH and the planned Phase 3 SERENADA study for PH-ILD are critical for the company's future and reputation.

Institutional investors hold a significant portion of Gossamer Bio, Inc.'s stock, with approximately 63.54% held by institutions. Major institutional owners include NEA Management Company, LLC, Octagon Capital Advisors LP, BlackRock, Inc., and Vanguard Group Inc. Individuals and insiders hold about 3.63% of the shares outstanding.